Copper Peptides vs GHK-Cu: What the Research Actually Shows
Last reviewed: September 2026
“Copper peptides” is one of the most-searched skincare terms in Canada, and almost nothing written about it explains what the phrase actually refers to. It is not a category of many molecules; in practice it means one — GHK-Cu, the copper complex of a three-amino-acid peptide — which appears on cosmetic labels under a different name again, copper tripeptide-1. This guide resolves the naming, summarises what the in-vitro, animal and human literature actually reports for skin and hair research, explains why a cosmetic serum and a research-grade vial of GHK-Cu are different products aimed at different buyers, and is candid about where the evidence stops. It does not sell a serum, because Quantum does not make one.
What are copper peptides?
Copper peptides are small peptides that bind copper(II) ions. The one that matters is glycyl-L-histidyl-L-lysine, or GHK — a tripeptide first isolated from human plasma in 1973 by Loren Pickart, who observed that it occurs naturally in the body bound to copper, and that its concentration in plasma is markedly higher in young adults than in older ones. That documented, age-related decline is the neutral fact that has framed research interest in the molecule for fifty years: it is an endogenous copper-carrying signal whose abundance changes with age, which makes it an obvious candidate for studies of tissue remodelling and repair. The research has run in cell culture, in animal wound models, in a handful of small human trials of topical formulations, and in gene-expression profiling. None of it has produced a Health-Canada-authorized product.
GHK-Cu, copper tripeptide-1, “copper peptides”: three names, one molecule
The naming confusion is the reason this page exists. The same substance travels under three names depending on who is talking.
| Name | Who uses it | What it refers to |
|---|---|---|
| GHK-Cu | Research literature, research suppliers | The copper(II) complex of the tripeptide glycyl-histidyl-lysine. “GHK” is the peptide; “-Cu” is the bound copper. |
| Copper tripeptide-1 | Cosmetic ingredient lists (INCI name) | Exactly the same molecule, as it must be declared on a cosmetic product label in Canada, the EU and the US. |
| Copper peptides | Marketing, search queries, blogs | Colloquial plural. In almost every product it means GHK-Cu; occasionally a formulator uses a related copper-binding peptide, but the research base is GHK-Cu’s. |
So when a serum lists “copper tripeptide-1” and a research supplier lists “GHK-Cu,” they are naming the same molecule — at radically different concentrations, purities and levels of documentation, which is the subject of the serum-versus-research section below. The research shorthand you will also see is “GHK” alone (the peptide without copper) and “Cu-GHK,” both of which are the same thing again.
What in-vitro and animal research reports
The GHK-Cu literature is unusually broad for a research peptide, and unusually old. The recurring findings, each tied to the model in which it was observed, are these. In cultured human dermal fibroblasts, GHK-Cu has been reported to increase synthesis of collagen and of glycosaminoglycans such as decorin, and to modulate the balance of matrix metalloproteinases and their inhibitors — the enzymes that break down and rebuild the extracellular matrix. In rodent and other animal wound models, GHK-Cu-treated wounds have been reported to close faster and show more organised collagen deposition than controls. In gene-expression profiling of cultured cells exposed to GHK, a large number of genes — the widely cited figure is roughly a third of those measured — shifted expression, with the pattern interpreted by the authors as a reset toward a younger or repair-oriented profile. Those are the findings, in the models in which they were found; the leap from a fibroblast dish or a rat wound to a human face is the leap that the rest of this page keeps refusing to make.
Skin-research findings
Human evidence exists but is small. The most-cited controlled trial applied a topical GHK-Cu formulation to the facial skin of women in roughly the 40-to-65 age range for twelve weeks and reported instrument-measured reductions in wrinkle volume and improvements in skin density and thickness relative to placebo or comparator — a real result, with real limits: a small cohort, a single formulation at a concentration the trial chose, cosmetic-grade outcome measures, and industry involvement typical of cosmetic studies. It is one trial, not a body of evidence, and it concerns a finished topical product, not a research reagent. The broader background on the molecule is on our GHK-Cu overview.
Hair-research findings
The hair literature is thinner than the marketing suggests. In animal and follicle-culture models, GHK-Cu and related copper-peptide compounds have been reported to enlarge follicle size and prolong the growth phase of the hair cycle; the compound the marketing usually leans on is actually a different, related peptide analogue studied in the 1990s, not GHK-Cu itself. Human hair-growth evidence for GHK-Cu is essentially anecdotal or confined to very small, uncontrolled observations. That is the honest position, and it is the position on our GHK-Cu and hair research page as well: the mechanism is plausible and the animal data are suggestive, and there is no human trial that establishes anything.
Copper peptide serums vs research-grade material
The single most useful thing to understand about “copper peptides” is that two entirely different products share the name.
A copper peptide serum is a finished cosmetic. It contains copper tripeptide-1 at a low concentration — typically a fraction of a percent, often undisclosed — in a water- or gel-based formulation with stabilisers, humectants and preservatives, and it is sold for application to intact skin under cosmetic regulations, which in Canada means it may not make therapeutic claims and is not assessed for efficacy before sale. Research-grade GHK-Cu is a raw material: lyophilised powder in a sealed vial, typically 50 or 100 mg of the pure copper-peptide complex, tested per batch by HPLC and mass spectrometry, supplied for laboratory research only, and never intended for application to a person.
The penetration caveat. Published skin-permeation work on GHK-Cu applied topically reports that the peptide accumulates in the stratum corneum — the dead outer layer — and does not meaningfully reach the viable dermis, where the fibroblast findings above were generated, unless the barrier is disrupted by techniques such as microneedling. That single finding does a lot of work. It explains why the cell-culture results and the modest human-trial results are so different in scale, it explains why serum concentration and formulation matter more than the ingredient’s name, and it is the reason a research supplier can describe the fibroblast literature honestly without implying that a serum reproduces it.
We are not going to rank serums, and we do not sell one. What can be said about any copper peptide product on a shelf is what to look for on its label: the INCI name “copper tripeptide-1” (rather than a vague “copper peptide complex”), a disclosed concentration, and a formulation that acknowledges the ingredient’s known sensitivity to light and to certain other actives. What “research-grade” means is a different checklist entirely: a per-batch Certificate of Analysis with an HPLC purity figure and mass-spectrometry identity confirmation, a batch number on the vial that matches the published report, and research-use-only labelling. Those are the criteria Quantum publishes for its GHK-Cu research peptide, with every batch report on the lab results page.
Limitations and open questions
A guide that only reported the promising findings would be marketing. The limitations are as well documented as the findings. Copper is an essential trace element and also toxic at inappropriate concentrations; GHK’s value as a copper carrier is precisely that it chelates the ion, and the free-copper content of a formulation matters. GHK-Cu is unstable in solution over time and sensitive to light, and the literature on formulation stability is a significant part of why topical results vary. The human evidence base is small, cosmetic-grade and largely industry-adjacent, and there is no large independent trial for any skin or hair endpoint. No regulator, including Health Canada, has approved GHK-Cu for any therapeutic use, and its status in cosmetics is that of an ingredient permitted for use, not an ingredient shown to do anything. And the mechanism that makes it interesting — broad shifts in gene expression — is also a reason for caution: broad is not the same as targeted, and what a fibroblast culture does in response to a signal is not what a whole organism does.
Sourcing research-grade GHK-Cu in Canada
For laboratory work, the criteria are the ones above: per-batch third-party COA, HPLC purity with MS identity, batch traceability on the vial, domestic dispatch, and research-use-only discipline from the supplier. Quantum stocks GHK-Cu in 50 mg and 100 mg lyophilised vials, tested by Peptide Test Canada, with the current batch reports on the Certificate of Analysis hub. The process of sourcing and verifying any research peptide in Canada is covered in how to buy research peptides in Canada, the legal framework in are peptides legal in Canada?, and the reason research peptides are supplied as lyophilised vials rather than finished consumer formats in the formats guide. The wider compound reference is in the peptide guide, and the catalogue is in the shop.
Frequently asked questions
Are copper peptides and GHK-Cu the same thing?
Almost always, yes. “Copper peptides” is the colloquial plural, “copper tripeptide-1” is the cosmetic-label (INCI) name, and “GHK-Cu” is the research name — all three refer to the copper(II) complex of the tripeptide glycyl-histidyl-lysine. The differences between products lie in concentration, purity and documentation, not in the molecule.
What does the research on copper peptides for hair actually show?
In animal and follicle-culture models, GHK-Cu and related copper-peptide analogues have been reported to enlarge follicles and prolong the growth phase of the hair cycle. Human evidence is limited to very small or uncontrolled observations; there is no controlled human trial establishing a hair-growth effect for GHK-Cu, and much of the marketing draws on a related analogue rather than GHK-Cu itself.
Do copper peptide serums penetrate the skin?
Published permeation studies report that topically applied GHK-Cu accumulates in the stratum corneum, the outer dead layer, and does not meaningfully reach the viable dermis unless the skin barrier is disrupted, for example by microneedling. That is why cell-culture findings, which expose fibroblasts directly, do not translate straightforwardly to a serum applied to intact skin.
What is the difference between a cosmetic serum and research-grade GHK-Cu?
A serum is a finished cosmetic containing copper tripeptide-1 at a low, often undisclosed concentration in a formulated base, sold for application to skin under cosmetic rules. Research-grade GHK-Cu is lyophilised raw material — typically 50 or 100 mg of the pure complex in a sealed vial — tested per batch by HPLC and mass spectrometry, with a published Certificate of Analysis, and supplied for laboratory research only.
Why doesn’t Quantum Peptides sell copper peptide serum or cream?
Because Quantum supplies lyophilised research materials for laboratory use, not cosmetics for application to people. A serum is a consumer product with a different purpose, different regulation and different buyer; research-grade GHK-Cu with a per-batch COA is what a laboratory needs, and it is the only format we offer.
GHK-Cu is supplied for laboratory research use only and is not for human or veterinary use. Literature statements summarise published in-vitro, animal and small human-trial findings and are not claims about any product. Page last reviewed September 2026.